Donor selection criteria to enhance the GVL effect
| Criteria . | HLA-matched unrelated-donor or cord-blood HCT . | T cell–depleted haploidentical HCT . | T-cell replete haploidentical HCT . |
|---|---|---|---|
| NK cell alloreactivity | Not clear6,7 | Advantage in adult AML and pediatric ALL1,2,4 | Not clear7,8 |
| Mother as donor | N/A | Advantage13 | Father as donor preferred over mother14,73 |
| Activating KIR genes/B haplotypes | Possible advantage17,18 | Possible advantage4 | Not clear74 |
| Criteria . | HLA-matched unrelated-donor or cord-blood HCT . | T cell–depleted haploidentical HCT . | T-cell replete haploidentical HCT . |
|---|---|---|---|
| NK cell alloreactivity | Not clear6,7 | Advantage in adult AML and pediatric ALL1,2,4 | Not clear7,8 |
| Mother as donor | N/A | Advantage13 | Father as donor preferred over mother14,73 |
| Activating KIR genes/B haplotypes | Possible advantage17,18 | Possible advantage4 | Not clear74 |
Evidence for the role of some criteria for donor selection that aim to enhance the GVL effect and reduce leukemia relapse.
N/A, not applicable.